首页 / 院系成果 / 成果详情页

Mesenchymal stem cells combined with IFN-γ treatment versus mesenchymal stem cells monotherapy: safety and efficacy over five years extension follow-up 期刊论文

编号：

3125D99FD011F1BD66DD4B62CB86386B
作者：

Yang, Yi#^[1,3]He, Xiao#^[1,2,3]Yao, Mengwei^[3];Li, Zhan^[3];Xing, Wei^[3];Zheng, Song Guo(郑颂国)*^[4,5,6]Xu, Xiang(徐祥)*^[2,3]
语种：

英文
期刊：

STEM CELL RESEARCH & THERAPY ISSN：1757-6512 2025 年 16 卷 1 期 ; NOV 17
收录：
关键词：

Rheumatoid arthritis Mesenchymal stem cell Interferon gamma Long-term extension study
摘要：

Background To report long-term safety and efficacy of mesenchymal stem cells (MSCs) in combination with and without IFN-gamma in patients with rheumatoid arthritis (RA), using pooled data from two randomised clinical trials followed by long-term extension (LTE) study. Methods Cumulative data from two phase 1/2 core trials and their LTE studies were analysed. Safety variables assessed included treatment-emergent adverse events (AEs), serious AEs (SAEs) and laboratory results. Efficacy assessments included ACR20/50/70 responses, Disease Activity Score 28 < 2.6 (remission) and <= 3.2 (LDA, low disease activity). Results A total of 110 patients received MSCs monotherapy and MSCs combined with IFN-gamma treatment. Event rates per 100 patient-years in MSCs monotherapy group and MSCs combined with IFN-gamma treatment group, respectively, were 2.47 and 2.31 for SAEs. No increase in the rate of any AE was observed over five years. Clinical response rates remained stable during the LTE study. Initial improvements in LDA/remission observed at year one were sustained over five years of follow-up in both groups, while the MSCs combined with IFN-gamma treatment group had higher ACR20 and LDA rates than the MSCs monotherapy group at both one year (100% versus 50.7%, p < 0.001; 39.3% versus 8.7%, p < 0.001) and five years (89.3% versus 44.9%, p < 0.001; 42.9% versus 8.7%, p < 0.001). Conclusion The long-term safety and efficacy of MSCs with/without IFN-gamma combination therapy remained stable. The efficacy of MSCs was maintained through at least five years. These findings support MSCs as a treatment option for patients with active RA.
推荐引用方式
GB/T 7714：

Yang Yi,He Xiao,Yao Mengwei, et al. Mesenchymal stem cells combined with IFN-γ treatment versus mesenchymal stem cells monotherapy: safety and efficacy over five years extension follow-up [J].STEM CELL RESEARCH & THERAPY,2025,16(1).
APA：

Yang Yi,He Xiao,Yao Mengwei,Li Zhan,&Xu Xiang.(2025).Mesenchymal stem cells combined with IFN-γ treatment versus mesenchymal stem cells monotherapy: safety and efficacy over five years extension follow-up .STEM CELL RESEARCH & THERAPY,16(1).
MLA：

Yang Yi, et al. "Mesenchymal stem cells combined with IFN-γ treatment versus mesenchymal stem cells monotherapy: safety and efficacy over five years extension follow-up" .STEM CELL RESEARCH & THERAPY 16,1(2025).
入库时间：

2025/11/30 21:56:48
更新时间：

2025/12/7 23:56:38

浏览次数：83  下载次数：0

分享到：

浏览次数：83

下载次数：0

打印次数：0